Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study
Open Access
- 19 October 2022
- journal article
- research article
- Published by Elsevier BV in Cell Reports Medicine
- Vol. 3 (11), 100785
- https://doi.org/10.1016/j.xcrm.2022.100785
Abstract
No abstract availableThis publication has 55 references indexed in Scilit:
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2018
- Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 studyAnnals of Oncology, 2017
- Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real WorldJAMA Oncology, 2017
- Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial CarcinomaPLOS ONE, 2015
- Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladderBritish Journal of Cancer, 2015
- Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Is Low Among Major European Centres: Results of a Feasibility QuestionnaireEuropean Urology, 2012
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- Contemporary use of perioperative cisplatin‐based chemotherapy in patients with muscle‐invasive bladder cancerCancer, 2010
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical TrialClinical Cancer Research, 2010
- Generalizability of cancer clinical trial resultsCancer, 2006